Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4331452 | 0.95 | SLC18A2 (0.46) | SLC18A2CYP1A2CYP2D6HIF1A | |
| SCHEMBL2603270 | 0.87 | SLC18A2 (0.50) | SLC18A2 | |
| SCHEMBL13995045 | 0.87 | SLC18A2 (0.50) | SLC18A2 | |
| SCHEMBL2603288 | 0.83 | SLC18A2 (0.49) | SLC18A2 | |
| SCHEMBL20419217 | 0.80 | SLC18A2 (0.46) | SLC18A2 | |
| SCHEMBL11461803 | 0.79 | SLC18A2 (0.45) | SLC18A2CYP1A2CYP2D6HIF1A | |
| SCHEMBL17114374 | 0.79 | SLC18A2 (0.45) | SLC18A2CYP1A2CYP2D6HIF1A | |
| SCHEMBL7250816 | 0.79 | SLC18A2 (0.45) | SLC18A2CYP1A2CYP2D6HIF1A | |
| SCHEMBL17114376 | 0.79 | SLC18A2 (0.45) | SLC18A2CYP1A2CYP2D6HIF1A | |
| SCHEMBL3764570 | 0.78 | HTR6 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140904-B1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6800636-B2 | FOR THERAPY OF CANCER | SCHERING CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | GUZI TIMOTHY (US) | 2003-02-27 | — | — | US | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | FNTA, FNTB, CETP | SLC18A2 4098/4885CYP1A2 4086/4885CYP2D6 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.